NWBO NORTHWEST BIOTHERAPEUTICS INC
Pharmaceutical Preparations · OTC · SEC CIK 1072379 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY204.8%
TTM net income YoY55.8%
TTM EPS YoY50.0%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,608.8%
Net margin-1,388.8%
FCF margin-1,557.6%
EBITDA margin-1,517.8%
Returns
ROE—
ROA-74.3%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets160.8%
Debt / equity—
Current ratio0.03x
Interest coverage-4.89x
Cash quality & payout
Operating cash flow / net income1.09x
Accruals ratio6.6%
Payout ratio—
Capex / revenue45.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.38M | $1.38M |
| R&D expense | $28.79M | $34.89M |
| SG&A expense | $32.51M | $33.00M |
| Operating income | -$59.91M | -$66.51M |
| Interest expense | $8.70M | $7.77M |
| Pretax income | -$60.70M | -$83.78M |
| Income tax | -$537,000 | $0 |
| Net income | -$60.16M | -$83.78M |
| EBITDA | -$57.85M | -$64.76M |
| EPS (basic) | -0.04 | -0.07 |
| EPS (diluted) | -0.04 | -0.07 |
| Weighted avg. shares (diluted) | 1.46B | 1.24B |
| Balance sheet | ||
| Cash & equivalents | $3.04M | $2.17M |
| Current assets | $5.52M | $4.06M |
| PP&E, net | $17.41M | $16.20M |
| Goodwill | $626,000 | $626,000 |
| Intangibles | $53.19M | $1.29M |
| Total assets | $81.29M | $26.73M |
| Current liabilities | $91.70M | $68.27M |
| Long-term debt | $60.04M | $62.68M |
| Total debt | $60.04M | $62.68M |
| Total liabilities | $128.86M | $105.71M |
| Shareholders' equity | -$60.28M | -$94.49M |
| Net debt | $57.00M | $60.50M |
| Shares outstanding | 1.56B | 1.33B |
| Cash flow statement | ||
| Operating cash flow | -$44.76M | -$57.02M |
| Capital expenditure | $1.50M | $1.01M |
| Free cash flow | -$46.27M | -$58.03M |
| Investing cash flow | -$1.81M | -$1.01M |
| Financing cash flow | $49.33M | $56.78M |
| Depreciation & amortization | $2.06M | $1.74M |
| Stock-based compensation | $1.21M | $3.46M |
Free plan shows the latest 2 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.